GLP-1 Receptor
Other GPCR & G Protein Inhibitors
| Cat.No. | Product Name | Information | Product Use Citations | Product Validations |
|---|---|---|---|---|
| S9851 | Danuglipron (PF-06882961) | Danuglipron (PF-06882961) is a non-peptide agonist that activates the canonical G protein signalling activity only in the Glucagon-like peptide-1 (GLP-1) receptor with Trp33ECD. | ||
| S8256 | Liraglutide | Liraglutide is a long-acting glucagon-like peptide-1(GLP-1) receptor agonist. |
|
|
| P1273New | Ecnoglutide（XW003） | Ecnoglutide (XW003) is a long-acting, cAMP-biased agonist of the GLP-1 Receptor that selectively enhances cAMP signalling over β-arrestin recruitment, and exhibits potential for the treatment of type 2 diabetes and obesity. | ||
| E1827 | AZD5004 (ECC5004) | ECC5004 (AZD5004, GLP-1 agonist (Eccogene)) is a small molecule GLP-1 Receptor Agonist (GLP-1RA) used to treat digestive system diseases and endocrine and metabolic diseases. ECC5004 has the potential to be used to treat obesity, type 2 diabetes and metabolic dysfunction-associated steatohepatitis (MASH) disease. | ||
| P1230 | Retatrutide (LY3437943) | Retatrutide (LY3437943) acts as a triple agonist peptide of the glucagon receptor (GCGR), glucagon-like peptide-1 receptor (GLP-1R) and glucosedependent insulinotropic polypeptide receptor (GIPR). Retatrutide binds to human GCGR, GLP-1R, and GIPR with EC50 values of 5.79, 0.775 nM, and 0.0643, respectively. Retatrutide has the potential for use in research on obesity. |
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.